Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein…

StudyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie· Mar 2010

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up.

Rita Ehrlich, Thomas A Ciulla, Adam M Moss, Alon Harris

Read paper

RetinaStudyTreatmentQ1IF 3.1

Combined injections were associated with lower central macular thickness at six months.

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up.

Rita Ehrlich … Alon Harris

Graefe's archive for clinical and experimental ophthalmology · Mar 2010 · Q1 in Ophthalmology

Purpose

To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (retinal vein occlusion).

Methods

Retrospective consecutive case series.

n = 16 patients

Results

lower thickness in the central retina, checked with an eye scan

527microm

Mean initial central m

379microm

mean central macular t

More results

Mean age and number of injections were 72.9 +/- 11.99 years, and 2 +/- 0.81 respectively.

In eight patients with central retinal vein occlusion, initial visual acuity was logMAR 1.09 +/- 0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98 +/- 0.55 (p = 0.59), 1.33 +/- 1.05 (p = 0.4) and 1.4 +/- 1.2 (p = 0.34) respectively.

More results

In eight patients with branch retinal vein occlusion, initial visual acuity was logMAR 1.025 +/- 0.58 and mean visual acuity at 1, 3, and 6 months was 0.56 +/- 0.21 (p = 0.05), 0.61 +/- 0.17 (p = 0.03) and 0.66 +/- 0.34 (p = 0.12) respectively.

“

Conclusion · 1 of 2

This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion.

Conclusion · 2 of 2

In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months.

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up.

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up.

Related papers